AU634655B2 - Pyridazinone derivative - Google Patents

Pyridazinone derivative Download PDF

Info

Publication number
AU634655B2
AU634655B2 AU76511/91A AU7651191A AU634655B2 AU 634655 B2 AU634655 B2 AU 634655B2 AU 76511/91 A AU76511/91 A AU 76511/91A AU 7651191 A AU7651191 A AU 7651191A AU 634655 B2 AU634655 B2 AU 634655B2
Authority
AU
Australia
Prior art keywords
group
straight chained
alkyl group
branched
hydrogen atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU76511/91A
Other languages
English (en)
Other versions
AU7651191A (en
Inventor
Takashi Matsumoto
Akira Saito
Ryozo Sakoda
Kenichi Shikada
Keizo Tanikawa
Nobutomo Tsuruzoe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nissan Chemical Corp
Original Assignee
Nissan Chemical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nissan Chemical Corp filed Critical Nissan Chemical Corp
Publication of AU7651191A publication Critical patent/AU7651191A/en
Application granted granted Critical
Publication of AU634655B2 publication Critical patent/AU634655B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/22—Nitrogen and oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
AU76511/91A 1990-04-25 1991-04-19 Pyridazinone derivative Expired AU634655B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP10991490 1990-04-25
JP2-109914 1990-04-25

Publications (2)

Publication Number Publication Date
AU7651191A AU7651191A (en) 1991-11-11
AU634655B2 true AU634655B2 (en) 1993-02-25

Family

ID=14522343

Family Applications (1)

Application Number Title Priority Date Filing Date
AU76511/91A Expired AU634655B2 (en) 1990-04-25 1991-04-19 Pyridazinone derivative

Country Status (17)

Country Link
US (3) US5202323A (enExample)
EP (1) EP0482208B1 (enExample)
JP (1) JPH07107055B2 (enExample)
KR (1) KR970002876B1 (enExample)
AT (1) ATE194835T1 (enExample)
AU (1) AU634655B2 (enExample)
CA (1) CA2053863C (enExample)
DE (1) DE69132329T2 (enExample)
DK (1) DK0482208T3 (enExample)
ES (1) ES2149761T3 (enExample)
GR (1) GR3034331T3 (enExample)
HU (1) HU208124B (enExample)
RU (1) RU2054004C1 (enExample)
TW (1) TW204348B (enExample)
UA (1) UA27031A1 (enExample)
WO (1) WO1991016314A1 (enExample)
ZA (1) ZA913134B (enExample)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU208124B (en) * 1990-04-25 1993-08-30 Nissan Chemical Ind Ltd Process for producing pyridazinone derivatives and pharmaceutical compositions comprising such derivatives as active ingredient
US5403590A (en) * 1992-12-21 1995-04-04 New England Deaconess Hospital Corporation Method of pulsatile drug infusion
IL110040A (en) * 1993-06-29 2000-07-16 Nissan Chemical Ind Ltd Pyridazinone derivatives their preparation and pharmaceutical compositions comprising them
JP3080131B2 (ja) 1993-06-29 2000-08-21 日産化学工業株式会社 ピリダジノン誘導体
US5763439A (en) * 1993-09-06 1998-06-09 Ishihara Sangyo Kaisha Ltd. Pyridazinone derivatives or their salts, processes for their production, and anti-shock agents containing them
NZ270130A (en) * 1993-12-16 1995-12-21 Nihon Nohyaku Co Ltd Pyridazinone derivatives, preparation and pharmaceutical compositions thereof
ES2147841T3 (es) * 1994-01-25 2000-10-01 Nissan Chemical Ind Ltd Derivados de piridazinona.
IL112695A (en) * 1994-02-22 1999-04-11 Green Cross Corp Pharmaceutical compositions containing pyridazinone derivatives
GB9514160D0 (en) * 1994-07-25 1995-09-13 Zeneca Ltd Aromatic compounds
US5670504A (en) * 1995-02-23 1997-09-23 Merck & Co. Inc. 2,6-diaryl pyridazinones with immunosuppressant activity
TW434240B (en) * 1995-06-20 2001-05-16 Zeneca Ltd Aromatic compounds, preparation thereof and pharmaceutical composition comprising same
SK282769B6 (sk) 1996-06-27 2002-12-03 Janssen Pharmaceutica N. V. N-[4-(Heteroarylmetyl)fenyl]heteroarylamín, spôsob jeho výroby a použitia, kompozícia na jeho báze
TW482675B (en) * 1997-01-31 2002-04-11 Green Cross Corp Compositions for oral administration containing pyridazinone compounds technical field of the invention
WO1999011268A1 (en) 1997-08-28 1999-03-11 Yoshitomi Pharmaceutical Industries, Ltd. Neovascularization promoters and neovascularization potentiators
RU2211217C2 (ru) * 1998-06-05 2003-08-27 Эгиш Дьёдьсердьяр Рт. Способ получения 5-хлор-4-аминозамещенного производного 3(2н)-пиридазинона
ATE272401T1 (de) 1998-09-01 2004-08-15 Nissan Chemical Ind Ltd Heilmittel für die stenose des rückenmarkkanals
CN1163230C (zh) * 1998-12-07 2004-08-25 日产化学工业株式会社 勃起功能障碍治疗剂
DE20009841U1 (de) * 2000-05-31 2001-10-25 Phyt-Immun GmbH, 66424 Homburg Nasensalbe auf Basis von Vaselin
ES2231685T3 (es) * 2001-04-05 2005-05-16 Torrent Pharmaceuticals Ltd Compuestos heterociclicos para complicaciones vasculares diabeticas y relacionadas con la edad.
US20050101631A1 (en) * 2002-08-01 2005-05-12 Otsuka Pharmaceuticals Company Process for producing carbostyril derivatives
US7399864B2 (en) * 2001-05-02 2008-07-15 Otsuka Pharmaceutical Co., Ltd. Process for producing carbostyril derivatives
EP1389467B1 (en) 2001-05-23 2013-07-03 Mitsubishi Tanabe Pharma Corporation Therapeutic composition for the regenerative treatment of cartilage diseases
JP4510384B2 (ja) 2001-05-23 2010-07-21 田辺三菱製薬株式会社 骨折治癒促進用組成物
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
CA2526586C (en) * 2003-09-09 2010-03-16 Biogen International Gmbh The use of fumaric acid derivatives for treating cardiac insufficiency, and asthma
JP4688681B2 (ja) * 2003-12-26 2011-05-25 日産化学工業株式会社 好中球増多抑制剤
WO2005074938A1 (ja) * 2004-02-09 2005-08-18 Nissan Chemical Industries, Ltd. 血管内膜肥厚抑制薬
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2321341B1 (en) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
JPWO2010074090A1 (ja) * 2008-12-25 2012-06-21 日産化学工業株式会社 ピリダジン−３（２ｈ）−オン化合物塩酸塩の結晶及びその製造方法
EP2448938B9 (en) 2009-06-29 2015-06-10 Incyte Corporation Pyrimidinones as pi3k inhibitors
AR079529A1 (es) * 2009-12-18 2012-02-01 Incyte Corp Derivados arilo y heteroarilo sustituidos y fundidos como inhibidores de la pi3k
WO2011075643A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted heteroaryl fused derivatives as pi3k inhibitors
WO2011099573A1 (ja) 2010-02-12 2011-08-18 大正製薬株式会社 徐放性製剤
EP2558463A1 (en) 2010-04-14 2013-02-20 Incyte Corporation Fused derivatives as i3 inhibitors
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
TW201249844A (en) 2010-12-20 2012-12-16 Incyte Corp N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors
EA201391254A1 (ru) 2011-03-01 2014-02-28 Синерджи Фармасьютикалз Инк. Способ получения агонистов гуанилатциклазы c
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
KR102030609B1 (ko) 2011-09-02 2019-10-11 인사이트 홀딩스 코포레이션 Ｐｉ３ｋ 억제제로서 헤테로시클릴아민
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
JP6499591B2 (ja) 2013-02-25 2019-04-10 シナジー ファーマシューティカルズ インコーポレイテッド 結腸洗浄において用いるためのグアニル酸シクラーゼ受容体アゴニスト
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
CN105764916B (zh) 2013-06-05 2021-05-18 博士医疗爱尔兰有限公司 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法
EP3492106B1 (en) 2013-08-09 2021-02-17 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
CN105722831B (zh) 2013-09-12 2019-08-06 艾丽奥斯生物制药有限公司 哒嗪酮化合物及其用途
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
DK3831833T3 (da) 2015-02-27 2022-11-14 Incyte Holdings Corp Fremgangsmåder til fremstillingen af en pi3k-inhibitor
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
CN107793362B (zh) * 2016-08-30 2022-04-22 江苏恩华药业股份有限公司 一种苯基哒嗪酮类衍生物的合成及其应用
CN119258070A (zh) 2018-06-01 2025-01-07 因赛特公司 治疗pi3k相关病症的给药方案
EP3972599B1 (en) 2019-05-21 2025-10-22 Ardelyx, Inc. Combination for lowering serum phosphate in a patient

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU597141B2 (en) * 1987-01-20 1990-05-24 Nissan Chemical Industries Ltd. 3(2h)pyridazinone, process for its preparation and antagonistic agent against srs-a containing it
EP0376079A1 (en) * 1988-12-20 1990-07-04 Nissan Chemical Industries Ltd. 3(2H)pyridazinones, processes for their preparation and antagonistic agent against SRS-A

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2534893A1 (de) * 1975-08-05 1977-02-17 Bayer Ag (thiono)(thiol)pyridazinonalkanphosphonsaeureester, verfahren zu ihrer herstellung sowie ihre verwendung als insektizide und akarizide
JPH0641455B2 (ja) * 1984-12-10 1994-06-01 日産化学工業株式会社 ピリダジノン誘導体
PT83530B (pt) * 1985-10-17 1989-05-31 Smith Kline French Lab Processo de preparacao de derivados da piridona, em especial derivados fenilicos
JP2550631B2 (ja) * 1987-01-20 1996-11-06 日産化学工業株式会社 ピリダジノン誘導体
IE62890B1 (en) * 1988-12-06 1995-03-08 Hafslund Nycomed Pharma New piperazinylalkyl-3(2h)-pyridazinones process for the preparation thereof and the use thereof as agents lowering blood pressure
HU208124B (en) * 1990-04-25 1993-08-30 Nissan Chemical Ind Ltd Process for producing pyridazinone derivatives and pharmaceutical compositions comprising such derivatives as active ingredient

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU597141B2 (en) * 1987-01-20 1990-05-24 Nissan Chemical Industries Ltd. 3(2h)pyridazinone, process for its preparation and antagonistic agent against srs-a containing it
EP0376079A1 (en) * 1988-12-20 1990-07-04 Nissan Chemical Industries Ltd. 3(2H)pyridazinones, processes for their preparation and antagonistic agent against SRS-A

Also Published As

Publication number Publication date
GR3034331T3 (en) 2000-12-29
HUT60253A (en) 1992-08-28
DE69132329D1 (de) 2000-08-24
HU913497D0 (en) 1992-01-28
RU2054004C1 (ru) 1996-02-10
EP0482208B1 (en) 2000-07-19
CA2053863A1 (en) 1991-10-26
ATE194835T1 (de) 2000-08-15
US5314883A (en) 1994-05-24
AU7651191A (en) 1991-11-11
JPH07107055B1 (enExample) 1995-11-15
KR970002876B1 (ko) 1997-03-12
JPH07107055B2 (ja) 1995-11-15
UA27031A1 (uk) 2000-02-28
DE69132329T2 (de) 2000-11-30
CA2053863C (en) 1996-10-29
TW204348B (enExample) 1993-04-21
EP0482208A1 (en) 1992-04-29
HU208124B (en) 1993-08-30
EP0482208A4 (en) 1992-10-07
US5318968A (en) 1994-06-07
ZA913134B (en) 1992-04-29
DK0482208T3 (da) 2000-09-18
ES2149761T3 (es) 2000-11-16
WO1991016314A1 (en) 1991-10-31
KR920701169A (ko) 1992-08-11
US5202323A (en) 1993-04-13

Similar Documents

Publication Publication Date Title
AU634655B2 (en) Pyridazinone derivative
JPWO1991016314A1 (ja) ピリダジノン誘導体
AU2008255733B8 (en) Novel 1,2,3,4-tetrahydroquinoxaline derivative which has, as substituent, phenyl group having sulfonic acid ester structure or sulfonic acid amide structure introduced therein and has glucocorticoid receptor-binding activity
KR20010040912A (ko) 신규 피리다진 유도체 및 이를 유효성분으로 하는 의약
RS50544B (sr) Derivati 1-piperazin-i 1-homopiperazin-karboksilata, postupci njihovog dobijanja i primena kao inhibitora faah enzima
US5476851A (en) Pyrazolo[3,4-g]quinoxaline compounds which inhibit PDGF receptor protein tyrosine kinase
SK287362B6 (sk) Derivát arylalkanoylpyridazínu, spôsob jeho prípravy a farmaceutický prostriedok, ktorý ho obsahuje
RU2392269C2 (ru) Производные арилоксиалкилкарбаматов, их получение и их применение в терапии
US5929074A (en) Pyridazinone derivatives with pharmaceutical activity
CA2446051A1 (en) Phthalazine derivatives with angiogenesis inhibiting activity
US5750523A (en) Pyridazinone derivatives
AU2002330656A2 (en) Substituted alkylaminopyridazinone derivatives, process for the preparation thereof and pharmaceutical composition containing the same
WO2003082263A1 (en) Sulfamic acids as inhibitors of human cytoplasmic protein tyrosine phosphatases
EP0419286A2 (en) Pyridone nitriles useful in treating cardiovascular disease
FR2933697A1 (fr) Derives de 1-benzyl-cinnolin-4-(1h)-one substitues, leur preparation et leur application en therapeutique
CA2020027C (en) Isoquinoline- or quinoline-sulfonamide derivative and a pharmaceutical composition comprising the same
JP3666042B2 (ja) ピリダジノン誘導体
JPH0717952A (ja) ベンジリデン誘導体
JPH0676390B2 (ja) ピリダジノン誘導体